Current Rating and Its Significance
MarketsMOJO’s 'Buy' rating for Suraksha Diagnostic Ltd indicates a positive outlook on the stock’s potential for capital appreciation and value creation. This rating is derived from a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Investors should understand that a 'Buy' rating suggests the stock is expected to outperform the broader market or its sector peers over the medium term, making it a favourable addition to a diversified portfolio.
Quality Assessment
As of 24 September 2026, Suraksha Diagnostic Ltd holds a 'good' quality grade. This reflects the company’s robust operational performance and sound financial health. Notably, the company demonstrates a strong ability to service its debt, with a Debt to EBITDA ratio of just 1.40 times, signalling manageable leverage and prudent financial management. Furthermore, the company’s operating profit has exhibited an impressive compound annual growth rate of 60.46%, underscoring its capacity to generate sustainable earnings growth.
The recent quarterly results reinforce this quality assessment. In June 2026, Suraksha Diagnostic reported a profit after tax (PAT) of ₹13.01 crores, marking a 61.7% increase compared to the average of the previous four quarters. Net sales for the quarter reached a record ₹87.65 crores, while PBDIT (Profit Before Depreciation, Interest, and Taxes) also hit a high of ₹30.44 crores. These figures highlight the company’s operational resilience and improving profitability trajectory.
Valuation Perspective
The valuation grade for Suraksha Diagnostic Ltd is currently assessed as 'fair'. The company’s return on capital employed (ROCE) stands at 15.5%, which is a respectable figure within the healthcare services sector. The enterprise value to capital employed ratio is 5.5, indicating that the stock is trading at a discount relative to its peers’ historical valuations. This discount could present an attractive entry point for investors seeking value in the microcap healthcare space.
Despite the positive returns, the price-to-earnings growth (PEG) ratio is relatively elevated at 27.2, reflecting the market’s expectations of continued earnings expansion. Over the past year, the stock has delivered a 13.67% return, while profits have grown modestly by 2%. This suggests that while the stock price has appreciated, earnings growth has been more measured, warranting a balanced view on valuation.
Financial Trend and Momentum
The financial trend for Suraksha Diagnostic Ltd is rated as 'positive'. The company has demonstrated a clear turnaround after two consecutive quarters of negative results, with the latest quarter showing strong profitability and sales growth. Year-to-date, the stock has gained 31.49%, and over the last six months, it has surged by 36.90%, signalling strong investor confidence and momentum.
Institutional investors hold a significant 36.7% stake in the company, which is a positive indicator. Institutional ownership often reflects thorough fundamental analysis and confidence in the company’s long-term prospects, providing additional support to the stock price and liquidity.
Technical Outlook
Technically, Suraksha Diagnostic Ltd is rated as 'bullish'. The stock has shown consistent upward price movement, with a one-month gain of 8.93% and a three-month gain of 29.79%. The recent slight dip of 0.11% on the day of analysis does not detract from the overall positive trend. This bullish technical stance suggests that the stock is in an upward momentum phase, which may continue to attract momentum-driven investors.
Rising fast and still accelerating! This Small Cap from FMCG sector is riding pure momentum right now. Jump in before the rally reaches its peak!
- - Accelerating price action
- - Pure momentum play
- - Pre-peak entry opportunity
What This Rating Means for Investors
For investors, the 'Buy' rating on Suraksha Diagnostic Ltd suggests that the stock is well-positioned to deliver favourable returns relative to its sector and the broader market. The combination of good quality fundamentals, fair valuation, positive financial trends, and bullish technical indicators provides a compelling case for considering this stock as part of a healthcare-focused portfolio.
However, investors should remain mindful of the microcap nature of the company, which can entail higher volatility and liquidity risks compared to larger, more established firms. The valuation metrics, while fair, also indicate that the market has priced in expectations of continued growth, which requires the company to sustain its operational momentum.
Overall, Suraksha Diagnostic Ltd’s current rating reflects a balanced but optimistic view, highlighting its potential as a growth-oriented investment within the healthcare services sector.
Summary of Key Metrics as of 24 September 2026
- Mojo Score: 75.0 (Buy Grade)
- Debt to EBITDA Ratio: 1.40 times
- Operating Profit CAGR: 60.46%
- Latest Quarterly PAT: ₹13.01 crores (61.7% growth vs previous 4Q average)
- Latest Quarterly Net Sales: ₹87.65 crores (highest recorded)
- ROCE: 15.5%
- Enterprise Value to Capital Employed: 5.5
- Institutional Holdings: 36.7%
- Stock Returns: 1Y +13.67%, YTD +31.49%, 6M +36.90%
These figures collectively underpin the 'Buy' rating and provide investors with a comprehensive snapshot of the company’s current standing.
Looking Ahead
Investors should continue to monitor Suraksha Diagnostic Ltd’s quarterly performance and sector developments, particularly given the dynamic nature of healthcare services. Sustained growth in profitability, prudent capital management, and maintaining favourable valuation levels will be key factors influencing the stock’s trajectory going forward.
In conclusion, Suraksha Diagnostic Ltd’s current 'Buy' rating by MarketsMOJO, supported by strong fundamentals and positive market sentiment, makes it a noteworthy candidate for investors seeking exposure to the healthcare services sector with a growth orientation.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
